A recent study has shed light on the potential of Rooibos tea compounds in the management of type 2 diabetes. Researchers delved into the mechanisms of action of Rooibos tea, focusing on a protein called dipeptidyl peptidase (DPP-IV), crucial for insulin production.
In the investigation, 37 secondary metabolites present in Rooibos tea were scrutinized for their interaction with DPP-IV. The study uncovered two promising compounds, esculin and nothofagin, which exhibited significant potential in enhancing insulin production by interacting with DPP-IV.
The research findings, published in Scientific African, showcased that these compounds formed stable complexes with DPP-IV, potentially modulating the enzyme's activity. This interaction could lead to improved insulin production, offering hope for better management of type 2 diabetes.
This breakthrough could pave the way for the development of new drugs derived from Rooibos tea compounds, offering potential relief for individuals grappling with type 2 diabetes.
Click
here to read more.